Full Name
Maura Bergen
Job Title
Global Managing Director, Health & Life Sciences
Company
FleishmanHillard
Speaking At
Speaker Bio
Maura has always had a passion for healthcare. She brings 30+ years of experience to FleishmanHillard and Omnicom PR (OPR) across several different healthcare sectors, including product, corporate communication, integrated, hospital and provider communications. Maura has been both a client and an advisor to some of the world’s leading healthcare companies and strives to consistently challenge the status quo and assess client needs to deliver integrated and innovative solutions that meet and exceed the demands of the ever-evolving communications landscape.
Maura has a depth of expertise across various therapeutic areas including oncology, immunology, cardiovascular metabolic health and obesity, T2 diabetes, and neuroscience/mental health, and with leading pharmaceutical companies including Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, GSK, Lilly, Novartis, Pfizer, Sanofi, Sanofi Pasteur, Merck, and Takeda.
Maura understands the needs of her clients because she has walked in their shoes, spending nearly five years at Novartis as Director of Product Communications in the Cardiovascular Business Unit. In that role she supported integrated communications approaches for the cardiovascular franchise, including hypertension blockbuster Diovan and the U.S. and Global launch of Exforge.
Maura’s work is especially influential in the area of diabetes, where she is a sought-after thought leader and NY Board Member of the American Diabetes Association (ADA). She was the program chair of the State of Diabetes: New York, which took place in October. The program, organized by ADA, brought together about 200 leaders from employers, health plans, providers and the government with the theme of advancing real-world programs focused on diabetes and obesity.
Prior to joining OPR’s FleishmanHillard, Maura led the health practice at Porter Novelli and recently joined FleishmanHillard to co-lead the Global Health Sector. Prior to joining OPR, Maura was an Executive Vice President and Leader in Cohn & Wolfe’s healthcare practice, a WPP Company, and Real Chemistry, where she led diverse communications teams with a focus on integrated marketing communications.
Maura has a depth of expertise across various therapeutic areas including oncology, immunology, cardiovascular metabolic health and obesity, T2 diabetes, and neuroscience/mental health, and with leading pharmaceutical companies including Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, GSK, Lilly, Novartis, Pfizer, Sanofi, Sanofi Pasteur, Merck, and Takeda.
Maura understands the needs of her clients because she has walked in their shoes, spending nearly five years at Novartis as Director of Product Communications in the Cardiovascular Business Unit. In that role she supported integrated communications approaches for the cardiovascular franchise, including hypertension blockbuster Diovan and the U.S. and Global launch of Exforge.
Maura’s work is especially influential in the area of diabetes, where she is a sought-after thought leader and NY Board Member of the American Diabetes Association (ADA). She was the program chair of the State of Diabetes: New York, which took place in October. The program, organized by ADA, brought together about 200 leaders from employers, health plans, providers and the government with the theme of advancing real-world programs focused on diabetes and obesity.
Prior to joining OPR’s FleishmanHillard, Maura led the health practice at Porter Novelli and recently joined FleishmanHillard to co-lead the Global Health Sector. Prior to joining OPR, Maura was an Executive Vice President and Leader in Cohn & Wolfe’s healthcare practice, a WPP Company, and Real Chemistry, where she led diverse communications teams with a focus on integrated marketing communications.
